Literature DB >> 15702605

Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

Stephen B Duffull1, Carl M J Kirkpatrick, Bruce Green, Nicholas H G Holford.   

Abstract

The aim of this report is to describe the use of WinBUGS for two datasets that arise from typical population pharmacokinetic studies. The first dataset relates to gentamicin concentration-time data that arose as part of routine clinical care of 55 neonates. The second dataset incorporated data from 96 patients receiving enoxaparin. Both datasets were originally analyzed by using NONMEM. In the first instance, although NONMEM provided reasonable estimates of the fixed effects parameters it was unable to provide satisfactory estimates of the between-subject variance. In the second instance, the use of NONMEM resulted in the development of a successful model, albeit with limited available information on the between-subject variability of the pharmacokinetic parameters. WinBUGS was used to develop a model for both of these datasets. Model comparison for the enoxaparin dataset was performed by using the posterior distribution of the log-likelihood and a posterior predictive check. The use of WinBUGS supported the same structural models tried in NONMEM. For the gentamicin dataset a one-compartment model with intravenous infusion was developed, and the population parameters including the full between-subject variance-covariance matrix were available. Analysis of the enoxaparin dataset supported a two compartment model as superior to the one-compartment model, based on the posterior predictive check. Again, the full between-subject variance-covariance matrix parameters were available. Fully Bayesian approaches using MCMC methods, via WinBUGS, can offer added value for analysis of population pharmacokinetic data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702605     DOI: 10.1081/bip-200040824

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  22 in total

1.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

2.  Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.

Authors:  Steven Kathman; Theingi M Thway; Lei Zhou; Stephanie Lee; Steven Yu; Mark Ma; Naren Chirmule; Vibha Jawa
Journal:  AAPS J       Date:  2016-01-19       Impact factor: 4.009

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

4.  The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Authors:  Lena E Friberg; Geoffrey K Isbister; L Peter Hackett; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12-12       Impact factor: 2.745

Review 6.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

8.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

9.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

10.  Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.

Authors:  Eleonora Marostica; Karel Van Ammel; Ard Teisman; Koen Boussery; Jan Van Bocxlaer; Filip De Ridder; David Gallacher; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-11       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.